We are live on ! Find out more
MDGL icon

Madrigal Pharmaceuticals
MDGL

68 hedge funds and large institutions have $9.88M invested in Madrigal Pharmaceuticals in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 30 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

9% less funds holding

Funds holding: 75 → 68 (-7)

39% less capital invested

Capital invested by funds: $16.3M → $9.88M (-$6.43M)

57% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 30

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
68
Holders Change
-7
Holders Change %
-9.33%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
13
Reduced
30
Closed
12
Calls
$20K
Puts
–
Net Calls
+$20K
Net Calls Change
+$71K

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$330K
2
RFC
Russell Frank Company
Washington
+$57.5K
3
SG Americas Securities
SG Americas Securities
New York
+$35.5K
4
Citigroup
Citigroup
New York
+$11.2K
5
WS
Wedbush Securities
California
+$10.7K

Top Sellers

1
AFM
Anson Funds Management
Texas
-$348K
2
Goldman Sachs
Goldman Sachs
New York
-$284K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$159K
4
SBIA
Sheaff Brock Investment Advisors
Indiana
-$113K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$90K
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
76
Ladenburg Thalmann Financial Services
Florida
– +$234 +28 +53%
1 2 3
4

MDGL Hedge Fund Activity: Q1 2016 in Review

68 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2016, worth a combined $9.88M — down 39% from $16.3M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of MDGL and 5 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 13 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $330K. The largest seller was Anson Funds Management, exiting entirely with an estimated $348K sold.

  • 68 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2016, down from 75 in Q4 2015.
  • Funds reported $9.88M of Madrigal Pharmaceuticals stock for Q1 2016, down 39% quarter-over-quarter.
  • 5 funds opened new Madrigal Pharmaceuticals positions in Q1 2016 and 12 closed out, a net change of -7 holders.
  • The largest Madrigal Pharmaceuticals buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $330K added.
  • The largest Madrigal Pharmaceuticals seller in Q1 2016 was Anson Funds Management, an estimated $348K sold.

Based on aggregated 13F filings for Q1 2016.